Protecting the World from Pertussis and Other Emerging Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure. The company currently distributes a portfolio of vaccines through an established global commercial network and continues to expand its operations across continents.
BioNet Key facts
3 licensed
recombinant pertussis vaccines
200+ qualified and passionate individuals fueling vaccine innovation
25+ years’ experience in vaccines
20 clinical trials conducts
10+ mRNA candidates
Latest News
Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses
The study demonstrates the effective delivery of a nucleic acid-based COVID-19 vaccine in a preclinical animal study utilizing Vaxxas’ high-density microarray patch (HD-MAP) technology. The DNA vaccine, owned by Technovalia and developed in partnership with BioNet, was conducted in collaboration with The University of Queensland. The research showed that HD-MAPs successfully delivered the vaccine to the skin of animals in a preclinical model, resulting in robust antibody and cell-based immune responses.
BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation
BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in collaboration with LTS Lohmann Therapie-Systeme AG, this recognition underscores BioNet’s contributions to mRNA vaccine technologies and their transformative potential to improve global health.
LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition
Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today their selection as a Concept Stage winner of the #PatchForwardPrize, a $50 million challenge by BARDA to advance microneedle patch-based RNA vaccine technologies. This recognition highlights the groundbreaking potential of their collaboration in mRNA vaccine development and delivery.